On. Target Molecules Biotech Inc has developed a fusion protein that causes apoptosis in several Cancer Cell Lines. Our novel antibody has been designed and engineered to cause natural cell death.
O.TM Biotech is developing its pioneering technology to simplify the diagnosis and treatment of cancer. We have been making rapid strides in fulfilling our mission which is to provide patients with an affordable treatment for cancer in an easy outpatient setting.
O.TM Biotech is committed to bringing its path-breaking treatment of cancer to patients. We are passionate about our work and strive every day to bring hope to cancer patients worldwide.
Driven by the need for developing a new approach to treating cancer and a genuine desire to make a difference
O.TM Biotech is developing a new technology platform to accelerate advancements in cancer research
On. Target Molecules Biotech Inc’s strength is in its acquired intellectual property, a seasoned team, a clear and focused plan for getting the product to the patient, addressing areas of high need and a very strong opportunity for expansion into multiple if not all cancer indications. The Methods used for Research & Development at O.TM Biotech are very unique and we are poised to create several molecules from the biotech platform.
The essential scope of the company is centered around proprietary innovation within the domain of disease therapeutics
O.TM Biotech has used innovative techniques, ingenuity, and cutting edge technologies to engineer its novel antibody to cause natural cell death in several cancer cell lines. Currently three variable sequences leading to eight therapeutically significant and viable drug products are in the pipeline. Building on the success to date, O.TM Biotech is poised to take on the remaining phases in its fight against cancer at scale and speed.
Our innovative research will have a tremendous impact in shaping global health care over the years to come.
O.TM BIOTECH INC UNCW Crest Research Park 5598 Marvin K. Moss Lane Wilmington NC 28409 USA